title: Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.
abstract: BACKGROUND
  The response to cytotoxic chemotherapy varies greatly in patients with advanced non-small cell lung cancer (NSCLC), and molecular markers may be useful in determining a preferable therapeutic approach for individual patients. This retrospective study was performed to evaluate the predictive value of ribonucleotide reductase regulatory subunit M1 (RRM1) on the therapeutic efficacy of platinum-based chemotherapy in patients with NSCLC.
  
  
  METHODS
  Patients with advanced NSCLC who received platinum doublet chemotherapy (n = 229) were included in this retrospective study, and their clinical outcomes were analyzed according to RRM1 expression.
  
  
  RESULTS
  In patients receiving gemcitabine-based therapy, the disease control rate (DCR) and progression-free survival (PFS) of patients with RRM1-negative tumors were significantly higher than in patients with RRMI-positive tumors (P = 0.041 and P = 0.01, respectively), and multivariate analysis showed that RRM1 expression was an independent prognostic factor (P = 0.013). No similar differences were found in patients receiving docetaxel- or vinorelbine-based therapy. In RRM1-positive patients, the DCRs for docetaxel and vinorelbine were higher than for gemcitabine (P = 0.047 and P = 0.047, respectively), and docetaxel and vinorelbine showed a longer PFS than gemcitabine-based chemotherapy (P = 0.012 and P = 0.007). No similar differences were found among patients with RRM1-negative tumors.
  
  
  CONCLUSIONS
  Negative RRM1 expression in advanced NSCLC is associated with a higher response rate to gemcitabine-based chemotherapy. In patients with RRM1-positive tumors, docetaxel and vinorelbine showed a higher therapeutic efficacy than gemcitabine-based therapy. Additional prospective studies are needed to investigate the predictive meaning of RRM1 in the response to chemotherapy.
authors.affiliation: Department of Thoracic Surgery, Second Hospital of Shandong University, Jinan, China.
authors.forename: Xiaopeng
authors.initials: X
authors.lastname: Dong
authors.affiliation: Department of Thoracic Surgery, Second Hospital of Shandong University, Jinan, China.
authors.forename: Yingtao
authors.initials: Y
authors.lastname: Hao
authors.affiliation: Department of Thoracic Surgery, Affiliated Hospital of Qingdao University Medical College, Qingdao, China.
authors.forename: Yucheng
authors.initials: Y
authors.lastname: Wei
authors.affiliation: Department of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, China.
authors.forename: Qiuwei
authors.initials: Q
authors.lastname: Yin
authors.affiliation: Department of Thoracic Surgery, Shandong Provincial Hospital, Jinan, China.
authors.forename: Jiajun
authors.initials: J
authors.lastname: Du
authors.affiliation: Department of Thoracic Surgery, Second Hospital of Shandong University, Jinan, China.
authors.forename: Xiaogang
authors.initials: X
authors.lastname: Zhao
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000378:metabolism*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D018572:Disease-Free Survival; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012262:Ribonucleoside Diphosphate Reductase; D043823:Taxoids / Q000627:therapeutic use; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000378:metabolism*; D014747:Vinblastine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077235:Vinorelbine; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D025521:Tumor Suppressor Proteins; D003841:Deoxycytidine; D000077143:Docetaxel; D014747:Vinblastine; C475286:RRM1 protein, human; D012262:Ribonucleoside Diphosphate Reductase; D000077235:Vinorelbine; D000093542:Gemcitabine